| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 142.34 | 32.5% | 52.4% |
| Total Income | 142.34 | 32.5% | 52.4% |
| Expenditure | 508.35 | 20.9% | 65.7% |
| PBT | -368.70 | 15.1% | 68.0% |
| Net Profit | -370.02 | 15.0% | 67.8% |
| OPM | — | ||
| NPM | — | ||
| EPS | -1.75 | 2.9% | 37.8% |
Insmed Reports Q3 2025 Revenue of $142.3 Million, Up 52% YoY
04 May 2026 · 4 May, 8:24 am
Summary
Insmed Incorporated reported financial results for the third quarter ended September 30, 2025. Total revenues for the quarter were $142.3 million, representing a 52% increase compared to the same period in 2024. ARIKAYCE revenue grew by 22% to $114.3 million, while BRINSUPRI generated $28.1 million in its initial quarter post-FDA approval. The company has raised its full-year 2025 global ARIKAYCE revenue guidance to a range of $420 million to $430 million. Insmed reported a net loss of $370.0 million, or $1.75 per share, for the third quarter of 2025.
Key Highlights
- 1
Insmed's BRINSUPRI was approved by the FDA as the first and only treatment for non-cystic fibrosis bronchiectasis.
- 2
BRINSUPRI total revenue reached $28.1 million for the third quarter of 2025.
- 3
ARIKAYCE total revenue was $114.3 million for the third quarter of 2025, reflecting 22% growth over the third quarter of 2024.
- 4
The company raised its 2025 global ARIKAYCE revenue guidance range to $420 million to $430 million, reflecting double-digit growth compared to 2024.
- 5
Insmed anticipates initiating the PALM-ILD Phase 3 study of TPIP for PH-ILD in the fourth quarter of 2025.
- 6
The Phase 2b CEDAR study of Brensocatib in patients with HS is now fully enrolled, with topline data anticipated in the first half of 2026.
Management Comments
Will Lewis
“The third quarter of 2025 celebrated the FDA approval of BRINSUPRI and the availability of our second commercial product, underscoring our team’s dedication to bringing forward a first-in-disease therapy for patients with non-cystic fibrosis bronchiectasis. While still early in the U.S. BRINSUPRI launch, we are very encouraged by positive feedback received from both physicians and patients.” “This achievement is just the beginning of numerous commercial and clinical catalysts anticipated over the next 18 months across our late-stage programs – ARIKAYCE, brensocatib, and TPIP – and our growing clinical pipeline of first- or best-in-class therapies. With these opportunities ahead, our team is more dedicated than ever to transforming the lives of patients with serious diseases.”
Informational and educational content only. Not investment advice.